EUVIMEDEUVIMED entdecken
Crossref

SERPINH1 secretion by cancer-associated fibroblasts promotes hepatocellular carcinoma malignancy through SENP3-mediated SP1/SQLE pathway

Hua Xiao, Zhaoying Yao, Tao Li, Xin Fang, Xuejiao Xu, Sheng Hu, Ya Yang, Chenchen Jin, Yuxiang Fei, Chao Liu, Qianming Du

International Immunopharmacology · 2025

DOI: 10.1016/j.intimp.2025.114259 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Hua Xiao und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery Nanjing First Hospital Nanjing Medical University Nanjing Jiangsu PR China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Cancer-Associated Fibroblasts, Sp1 Transcription Factor. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer-associated fibroblasts (CAFs) have garnered significant attention due to their ability to shape the tumor microenvironment, thereby facilitating tumor progression and metastasis. Serpin peptidase inhibitor clade H member 1 (SERPINH1) is known for its role in the proper folding and secretion of collagen. However, its biological significance in hepatocellular carcinoma (HCC) remains unclear. We observed higher levels of SERPINH1 in the conditioned medium (CM) of CAFs compared to normal fibroblasts (NFs) via ELISA assays. To investigate its impact on HCC, we knocked down SERPINH1 in CAFs by shRNA, which led to a notable reduction in HCC cell proliferation, migration, and invasion induced by CM of CAFs, measured by colony formation and Transwell assays. SERPINH1 also inhibited HCC cell apoptosis, decreased the percentage of cells arrested in the G0/G1 phase, and increased the proportion of cells in the S phase, which were detected by flow cytometry. We further performed co-injections of HepG2 cells liver orthotopic transplantation model with either shCtrl-CAFs or shSERPINH1-CAFs. Interestingly, the presence of shCtrl-CAFs significantly enhanced tumor-initiating capacity compared to HepG2 cells alone or when co-injected with shSERPINH1-CAFs. Mechanistically, CAFs-derived SERPINH1 activated the SENP3/SP1 signaling pathways, substantially promoting the growth of HCC cells. Notably, we found that the transcription factor SP1 directly binds to the SQLE promoter and activates its transcription via ChIP-qPCR assay. Inhibition of SP1 expression using the specific inhibitor plicamycin effectively reversed CAFs-derived SERPINH1-induced HCC growth in vivo. Collectively, our findings highlighted the pathological role CAFs-derived SERPINH1 played in driving malignant of HCC cells through the SENP3/SP1/SQLE signaling axis, which offered a explanation of how SERPINH1 promotes HCC progress. Besides, we also demonstrated that targeting SERPINH1 signaling shall be a promising direction to develop effective therapeutical strategies for anti-HCC clinical management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsCancer-Associated FibroblastsSp1 Transcription FactorCysteine EndopeptidasesSerpinsHumansAnimalsSignal TransductionHep G2 CellsCell ProliferationMiceMice, NudeCell MovementApoptosisMaleMice, Inbred BALB CTumor MicroenvironmentAntigens, NeoplasmHSP47 Heat-Shock Proteins

Stichwörter der Autor:innen

CAFsHCC

Substanzen

Sp1 Transcription FactorSERPINH1 protein, humanCysteine EndopeptidasesSP1 protein, humansquamous cell carcinoma-related antigenSerpinsAntigens, NeoplasmHSP47 Heat-Shock Proteins

Autor:innen und Institutionen

  • Department of General Surgery Nanjing First Hospital Nanjing Medical University Nanjing Jiangsu PR China.
  • Department of Pharmacy, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, PR China.
  • General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, PR China; School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 210009, PR China.
  • School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 210009, PR China.
  • College of Pharmacy, Xinjiang Medical University, Urumqi 830054, PR China.
  • School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 210009, PR China; Department of Pharmacy, Nanjing First Hospital, Nanjing Medical University, Nanjing 210029, PR China. Electronic…

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Jiangsu Province

Zitieren

APA

Xiao, H., Yao, Z., Li, T., Fang, X., Xu, X., Hu, S., Yang, Y., Jin, C., Fei, Y., Liu, C., & Du, Q. (2025). SERPINH1 secretion by cancer-associated fibroblasts promotes hepatocellular carcinoma malignancy through SENP3-mediated SP1/SQLE pathway. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.114259

Vancouver

Xiao H, Yao Z, Li T, Fang X, Xu X, Hu S, et al. SERPINH1 secretion by cancer-associated fibroblasts promotes hepatocellular carcinoma malignancy through SENP3-mediated SP1/SQLE pathway. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.114259

BibTeX
@article{Xiao2025,
  author = {Xiao, Hua and Yao, Zhaoying and Li, Tao and Fang, Xin and Xu, Xuejiao and Hu, Sheng and Yang, Ya and Jin, Chenchen and Fei, Yuxiang and Liu, Chao and Du, Qianming},
  title = {SERPINH1 secretion by cancer-associated fibroblasts promotes hepatocellular carcinoma malignancy through SENP3-mediated SP1/SQLE pathway},
  journal = {International Immunopharmacology},
  year = {2025},
  doi = {10.1016/j.intimp.2025.114259}
}
Kostenlos starten →